Provided by Tiger Trade Technology Pte. Ltd.

Regulus Therapeutics

8.16
0.0000
Volume:- -
Turnover:75.91M
Market Cap:564.95M
PE:-11.28
High:8.16
Open:8.16
Low:8.16
Close:8.16
52wk High:8.35
52wk Low:0.8301
Shares:69.23M
Float Shares:52.94M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7233
EPS(LYR):-0.8227
ROE:-53.82%
ROA:-34.23%
PB:8.18
PE(LYR):-9.92

Loading ...

BRIEF-Novartis Completes Acquisition Of Regulus Therapeutics

Reuters
·
Jun 25, 2025

Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary

Reuters
·
Jun 25, 2025

Novartis' Tender Offer for Regulus Therapeutics Expires with 74.49% Shareholder Acceptance

Reuters
·
Jun 25, 2025

Novartis AG Announces Expiration of Antitrust Waiting Period for Regulus Therapeutics Acquisition

Reuters
·
Jun 23, 2025

Preston Klassen, President & Head of R&D, Reports Acquisition of Common Shares in Regulus Therapeutics Inc

Reuters
·
Jun 05, 2025

Novartis Ag - Novartis Announces Commencement of Tender Offer to Acquire Regulus Therapeutics

THOMSON REUTERS
·
May 27, 2025

Novartis Launches Tender Offer to Acquire Regulus Therapeutics for $7.00 Per Share Plus Contingent Value Right

Reuters
·
May 27, 2025

Novartis Ag - Offer Includes $7.00 Cash per Share Plus Contingent Value Right

THOMSON REUTERS
·
May 27, 2025

Novartis Ag - Offer Subject to Customary Conditions Including Hart-Scott-Rodino Act

THOMSON REUTERS
·
May 27, 2025

Novartis Ag - Offer to Expire on June 24, 2025

THOMSON REUTERS
·
May 27, 2025

Regulus Resources Inc. Unveils Corporate Presentation Highlighting AntaKori Copper-Gold Project and Long-Term Strategy

Reuters
·
May 21, 2025

Regulus Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate

Benzinga
·
May 09, 2025

Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 09, 2025

Regulus Therapeutics Reports Increased R&D and G&A Expenses in Q1 2025; Cash Runway Extends to Early 2026

Reuters
·
May 09, 2025

Regulus Therapeutics Q1 Basic EPS USD -0.15

THOMSON REUTERS
·
May 09, 2025

Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 06, 2025

Regulus Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
May 01, 2025

Oppenheimer Downgrades Regulus Therapeutics to Market Perform From Outperform

MT Newswires Live
·
May 01, 2025